Navigation Links
Can disclosure hurt the translation of research?

Boston, MA All major clinical trials now include disclosures detailing who funded the study to ensure transparency. However, is it possible that this transparency is actually hurting research? One might assume that the methodological rigor of the study matters to physicians more than the disclosure. However, in a new study, researchers at Brigham and Women's Hospital (BWH) have found that pharmaceutical industry sponsorship of a research study negatively influences physicians' perceptions of the study and their willingness to believe and act on the research findings. This study will be published in the September 20, 2012 issue of the New England Journal of Medicine (NEJM).

"We found that physicians downgraded their perceptions of industry funded research similarly for high-quality studies and low-quality studies," explained Aaron Kesselheim, MD, JD, assistant professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics at BWH, and principal investigator of this study.

The research team presented abstracts describing hypothetical clinical trials of three fictional, but potentially useful, new drugs to a national sample of board-certified internal medicine physicians. Each abstract was randomized to demonstrate high, medium, or low methodological rigor and randomized to report one of three disclosure variables: funding from a pharmaceutical company, funding by the National Institutes of Health (NIH), or no disclosure listed. The investigators then assessed physicians' impressions of the trials' rigor, their confidence in the results, and their willingness to prescribe the drugs.

"We found clear associations between the funding disclosure variations and physicians' perceptions of a trial's rigor and results," explained Dr. Kesselheim.

The results showed that physicians downgraded the credibility of industry-funded trials when compared with the same trials that had no funding listed, and to an even greater extent when compared with the same trials characterized as having NIH funding. The authors attributed these results to high-profile instances of unethical behavior by pharmaceutical companies sponsoring clinical research in the past decade.

Researchers emphasize that these findings have important implications. The pharmaceutical industry funds a substantial portion of clinical research, and a key determinant of the impact of a trial should be its methodological rigor, not its funding source, Dr. Kesselheim and his co-authors argue.

"While there is good reason to be extra vigilant about industry-funded research, if physicians are reluctant to trust all such research, this could hinder the translation of even high-quality industry-funded research into practice. Strategies such as greater transparency and independent review of trial data could be pursued to try to change such attitudes among physicians," Dr. Kesselheim suggested.


Contact: Jessica Maki
Brigham and Women's Hospital

Related medicine news :

1. Study finds non-disclosure of HIV serostatus common among India female sex workers
2. New federal disclosure law may have little impact on drugs prescribed
3. Penn Translational Medicine Institute to hold 7th Annual Symposium
4. Translation of research into practice for post-stroke care goes national
5. Weill Cornell awarded $1.8 million for translational blood cancer research
6. SU2C, Dutch Cancer Society announce new International Translational Cancer Research Grant recipients
7. U-Ms Taubman Institute awards inaugural $100,000 translational medical research prize
8. TMC institutions get $20 million renewal grant for translational medicine center
Post Your Comments:
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor ... Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension (PH) ... nominated by the public, will receive special recognition throughout 2016 as part of ...
(Date:11/25/2015)... ... 25, 2015 , ... Privately owned Contract Development and Manufacturing ... its current state of the art research, development and manufacturing facility outside of ... manufacturing capacity as well as to support its clients’ growing research and development ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of ... weight gain, cold hands, and dry skin. But many people who find their cholesterol ... exercise regimen instead of their thyroid, especially if they don’t have any of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  Today AVACEN Medical announced the issue of United States patent ... Adjustment ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific ... Photo - ... ... ...
(Date:11/25/2015)... YORK , November 25, 2015 ... market of self-monitoring blood glucose devices was valued at ... grow with a CAGR of 5.7% during 2015 - ... geriatric population and increasing prevalence of diabetes. In addition, ... diabetes care is also contributing to the growth of ...
(Date:11/25/2015)... Pennsylvania , November 25, 2015 - ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) --> ... Care Continuing Medical Education (CME) ... medical information products and services, will feature latest diagnostic imaging textbooks ...
Breaking Medicine Technology: